Articles On Biotron (ASX:BIT)
Title | Source | Codes | Date |
---|---|---|---|
Biotron (ASX:BIT) launches Covid-19 human study
Biotron (BIT) launches a human trial of its lead antiviral drug against COVID-19The trial of Biotron’s BIT225 compound has been approved as a sub-study of an ongoing phase two HIV-1 clinical trial, which is currently in progress in Thailand... |
themarketherald.com.au | BIT | 1 year ago |
Top 10 at 10: Which ASX stocks are on the gain train this morning?
Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers... |
Stockhead | BIT | 1 year ago |
Biotron announces phase 2 trial of BIT225 now fully recruited
Biotron (ASX:BIT) has announced that a Phase 2 HIV-1 clinical trial of its lead antiviral drug, BIT225, is fully recruited. |
BiotechDispatch | BIT | 1 year ago |
Closing Bell: Hands up if you’re an ex-PM about to be sued by BPH Energy, which has gained 235% today on the very prospect of it
The ASX 200 loses 1.2%, XEC sheds 0.9% Weak leads, sour sentiment hobble Asia-Pac markets BPH adds 200% on word ex-PM shot down its prospects The S&P/ASX Emerging Companies (XEC) index has lost 0.9% on Tuesday, the benchmark ASX 200... |
Stockhead | BIT | 1 year ago |
Biotron (ASX:BIT) finishes recruitment for BIT225 HIV-1 trial
Biotron (BIT) finishes recruiting patients for its phase two HIV-1 clinical trial of its lead antiviral drug BIT225 The clinical trial is being conducted in Thailand and aims to determine the safety and efficacy of BIT225 on a daily basis... |
themarketherald.com.au | BIT | 1 year ago |
Here are the Top 10 crucial trials coming up for ASX biotechs in 2022
What are the risks of investing in biotechs? How to value a biotech Top 10 crucial trials coming up for ASX biotechs in 2022 Risks of investing in biotechs Historical data shows that biotech is one the best sectors to put your money in ov... |
Stockhead | BIT | 1 year ago |
Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs
US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F... |
Stockhead | BIT | 1 year ago |
Check Up: These biotech themes got billions in VC funding. These ASX stocks could benefit
A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m... |
Stockhead | BIT | 1 year ago |
Biotron (ASX:BIT) receives positive FDA guidance for COVID-19 trial
Biotron (BIT) receives positive US FDA guidance for its lead antiviral drug, BIT225, as a potential treatment of COVID-19 The guidance follows the company sending a briefing package for a proposed phase two clinical trial Managing Director... |
themarketherald.com.au | BIT | 1 year ago |
ASX Health Stocks: Invion demonstrates efficacy, Biotron gets feedback from the FDA
Invion demonstrates high efficacy of INV043 when used as a combined therapy Biotron gets positive feedback from US FDA Biome stocks its Probiotics range on Priceline’s shelves Invion demonstrates efficacy Cancer fighter Invion (ASX:IVX) w... |
Stockhead | BIT | 1 year ago |
Closing Bell: Interest piqued? Not for sliding local markets on Rates Day
The interest rate rise came and the markets fell, then turned a corner. The question now is — will the wheels stay on? Already lagging, the ASX Emerging Companies (XEC) index has closed 0.8% lower. The benchmark has closed 0.4% behind. The... |
Stockhead | BIT | 1 year ago |
Biotron says BIT225 against SARS-CoV-2 infection effective in animals
Biotron (ASX:BIT) has announced its lead clinical drug BIT225 has demonstrated effective protection from severe disease in mice with established SARS-CoV-2 infection in a new animal study performed at The SCRIPPS Research Institute... |
BiotechDispatch | BIT | 1 year ago |
Closing Bell: Sinking local markets jump ship as Central Bank prepares to board
Central Banks have their fingers on the fun button this week, and the markets are pricing in the big push. The Emerging Companies Index (XEC) has been sunk on day dot, down 2.3%. The S&P/ASX 200 index was down 1.2% at 4.15pm, with this... |
Stockhead | BIT | 1 year ago |
Biotron share price rockets 38% on COVID trial results
Those that believe that COVID-19 is yesterday’s news should look at the Biotron Limited (ASX: BIT) share price today. Shares in the small cap biotech jumped 37.5% to 9.9 cents each after reporting positive COVID-19 animal trial results tod... |
Motley Fool | BIT | 1 year ago |
Biotron (ASX:BIT) finds BIT225 effective against established COVID-19 in mice
Biotech company Biotron (BIT) says a new study of its lead clinical drug, BIT225, has been shown to be effective against established SARS-CoV-2 in mice The study showed BIT225 to protect against severe disease in mice that were infected wi... |
themarketherald.com.au | BIT | 1 year ago |
Check Up: Money managers are still bullish on Healthcare; here’s what they said
The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week Dr Anthony Faucci, America’s top infectious disea... |
Stockhead | BIT | 1 year ago |
Check Up: Biotechs are going through a rough patch, but recent ASX IPOs haven’t flopped too badly
The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot... |
Stockhead | BIT | 2 years ago |
Check Up: More clinical trials and FDA funding boost. Is this the end of biotech’s woes?
Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve... |
Stockhead | BIT | 2 years ago |
Biotron updates on pre-clinical study of BIT225 in COVID-19
Biotron (ASX:BIT) says its lead clinical asset BIT225 has again demonstrated substantial and clinically meaningful efficacy against SARS-CoV-2 in a series of animal studies performed at The SCRIPPS Research Institute in the US.... |
BiotechDispatch | BIT | 2 years ago |
Closing Bell: Small caps rise, unemployment falls, more people accept life’s full of ups and downs
The Emerging Companies Index (XEC) climbed more than 2% higher on Thursday, before closing at 1.9%, while its benchmark colleague – the upmarket ASX 200 followed Wall Street’s ascendence, trading up a shade over 1% after the Fed lifted inte... |
Stockhead | BIT | 2 years ago |
Biotron (ASX:BIT) looks to human trial after COVID-19 drug success in animals
Biotron’s (BIT) lead drug, BIT225, has again demonstrated its effectiveness against SARS-CoV-2 (COVID-19) in animals The success of the second study was indicated by the significant prevention of body weight loss and no death reported in S... |
themarketherald.com.au | BIT | 2 years ago |
Check Up: The future of telehealth, and the best and worst performing ASX health stocks for the month
Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal... |
Stockhead | BIT | 2 years ago |
Check Up: Johnson & Johnson manoeuvre causes a stir, as CSL pulls Healthcare higher on the ASX
The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby... |
Stockhead | BIT | 2 years ago |
Check Up: As Omicron rages, rapid antigen testing specialist Atomo surges nearly 50pc
At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform... |
Stockhead | BIT | 2 years ago |
Check Up: Anteotech riding high with $1.9m refund, and Avecho inks supply agreement for CBD arthritis treatment
It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining. Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %... |
Stockhead | BIT | 2 years ago |
Healthcare has been a hot sector. Here are the top ASX biotech stocks in 2021
The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19 ravaged the world. Nasdaq-listed BioNTech, which... |
Stockhead | BIT | 2 years ago |
Closing Bell: ASX falls despite flurry of merger and acquisition action
While US markets rose after the Fed outlined plans to gradually withdraw stimulus, our markets did not follow suit even amidst a sea of deals. Leading the charge today was IGO (ASX:IGO) which after months of negotiations looks to have inked... |
Stockhead | BIT | 2 years ago |
Check Up: Neuren close to FDA drug approval and Compumedics fires up Aussie factory for medical wearables
It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining. Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont... |
Stockhead | BIT | 2 years ago |
November Winners: ASX investors were spooked by Omicron, but wooed by Julimar, hydrogen and the metaverse
For the second month in a row the ASX was hit by a major sell-off in the last few days of the month and it took the bourse from what was then a 0.5% gain to a 1.56% loss in November. Just when we thought we were out of the worst of COVID, w... |
Stockhead | BIT | 2 years ago |
Closing Bell: ASX makes up lost ground, still finishes 0.54% down
ASX recovered some lost ground in arvo trade but still finished 0.54% down, as markets continue to be shaken by the discovery of the omicron variant of COVID-19 and falling oil prices. Resources and tech managed to finish in the green – by... |
Stockhead | BIT | 2 years ago |
10 at 10: Investors in these ASX stocks can see light at the end of the tunnel this morning
Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov... |
Stockhead | BIT | 2 years ago |
ScoPo’s Powerplays: Christmas rally runs out of puff, but market awaits crucial release from Neuren
Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 25 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Theme of the week At the time... |
Stockhead | BIT | 2 years ago |
Market Highlights and 5 ASX Small Caps to watch on Friday
Wall Street closed for Thanksgiving No major leads from global markets overnight, as Wall Street was closed for Thanksgiving. Elsewhere, new data showed COVID infections in Europe continue to surge higher. With winter approaching, the conti... |
Stockhead | BIT | 2 years ago |
Biotron Drug Effective Against COVID-19 In Animals
BIT225 administered orally significantly reduced viral load in the lungs and blood of animals challenged with SARS-CoV-2. BIT225 protected against severe disease, indicated by the significant prevention of body weight loss in animals trea... |
FNArena | BIT | 2 years ago |
Closing Bell: One biotech more than doubles, another drops 30pc on debut
The ASX closed just 0.11% higher today but there were no shortage of small cap winners, led by Antiviral biotechnology stock Biotron (ASX:BIT). It announced that its lead drug candidate — BIT225 — had been shown to be effective against COVI... |
Stockhead | BIT | 2 years ago |
ASX Health Stocks: Biotron gets a boost with promising in vivo study for COVID-19 treatment
Antiviral biotechnology stock Biotron (ASX:BIT) turned heads on the ASX this morning, after announcing that its lead drug candidate — BIT225 — had been shown to be effective against COVID-19 in animals. After tracking from ~8c to below 5c t... |
Stockhead | BIT | 2 years ago |
Biotron’s (ASX:BIT) drug effective against COVID-19 in animals
Biotron’s (BIT) lead drug, BIT225, has been effective against COVID-19 in animals The drug was given orally and significantly reduced viral load in the lungs and blood Additionally, the company also tested BIT225 in an in-vitro study in c... |
themarketherald.com.au | BIT | 2 years ago |
The Biotron (ASX:BIT) share price just exploded 86% on COVID drug update
The Biotron Limited (ASX: BIT) share price is rocketing upwards today after the company announced its lead clinical asset successfully treated COVID-19 symptoms in mice as part of a study. In the study, the drug, BIT225, was found to reduc... |
Motley Fool | BIT | 2 years ago |
Biotron's BIT225 effective against COVID-19 in animal study
Biotron (ASX:BIT) has announced that its lead clinical asset, BIT225, has demonstrated substantial and clinically meaningful efficacy against SARS-CoV-2 in a series of animal and cell-based studies performed at The SCRIPPS Research... |
BiotechDispatch | BIT | 2 years ago |
10 at 10: These ASX stocks are the most imposing this morning
Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov... |
Stockhead | BIT | 2 years ago |
Check Up: Sustainable Nutrition riding high and Singular Health branches out from… health
It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining. Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M... |
Stockhead | BIT | 2 years ago |
Biotron commences two new clinical trials of BIT225
Biotron (ASX:BIT) has commenced two clinical trials with its lead antiviral drug BIT225 in HIV-1-positive populations. |
BiotechDispatch | BIT | 2 years ago |
Biotron commences two new clinical trials of BIT225
Biotron (ASX:BIT) has commenced two clinical trials with its lead antiviral drug BIT225 in HIV-1-positive populations. |
BiotechDispatch | BIT | 2 years ago |
Check Up: Dimerix and ImpediMed announced breakthroughs, while earnings dominate news flow in August
Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat... |
Stockhead | BIT | 2 years ago |
Dr Boreham’s Crucible: With five trials and $100m, cancer-hunter Clarity’s future is clear
In the spirit of the recently-concluded Olympics and ongoing Paralympics, congratulations to the backers of the radiopharmaceuticals group for a record-breaking performance after listing this week. In raising $92 million, Clarity (ASX:CU6)... |
Stockhead | BIT | 2 years ago |
Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress
It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N... |
Stockhead | BIT | 2 years ago |
Check Up: Hexima roars 70pc on clinical trials, while Bionomics heads for a US dual listing
The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du... |
Stockhead | BIT | 2 years ago |
Check Up: Rhythm (ASX:RHY) plans US expansion, the US$1.5b dog dermatitis market and data dumps drive stocks down
It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by Rhinomed (ASX:RNO)... |
Stockhead | BIT | 2 years ago |
Check up: A mixed bag for ASX health stocks as FDA decides fates at the flip of a coin
It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals... |
Stockhead | BIT | 2 years ago |
Check Up: As Alzheimer’s grabs the spotlight, these ASX biotech stocks also impressed
Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U... |
Stockhead | BIT | 2 years ago |